# SUMMARY OF PRODUCT CHARACTERISTICS

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Milpro 12.5 mg/125 mg film-coated tablets for dogs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

**Active substances:**

| | |
|---|---|
| Milbemycin oxime | 12.5 mg |
| Praziquantel | 125 mg |

**Excipients:**

| **Qualitative composition of excipients and other constituents** |
|---|
| **Core:** |
| Microcrystalline cellulose |
| Croscarmellose sodium |
| Lactose monohydrate |
| Starch, pregelatinised |
| Povidone |
| Magnesium stearate |
| Silica hydrophobic colloidal |
| **Coat:** |
| Natural Poultry liver flavour |
| Hypromellose |
| Microcrystalline cellulose |
| Macrogol stearate |

Round shaped, beige to pale brown meat flavoured tablets.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs

## 3.2 Indications for use for each target species

In dogs: treatment of mixed infections by adult cestodes (tapeworms) and nematodes (roundworms) of the following species:
Cestodes:
*Dipylidium caninum*
*Taenia* spp.,
*Echinococcus* spp.,
*Mesocestoides* spp.
Nematodes:
*Ancylostoma caninum,*
*Toxocara canis,*
*Toxascaris leonina,*
*Trichuris vulpis,*
*Thelazia callipaeda* (see specific treatment schedules under section 3.9 “Administration routes and dosage”),
*Crenosoma vulpis* (reduction of the level of infection),
*Angiostrongylus vasorum* (reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under section “3.9 Administration routes and dosage”).

The veterinary medicinal product can also be used in the prevention of heartworm disease (*Dirofilaria immitis*), if concomitant treatment against cestodes is indicated.

## 3.3 Contraindications

Do not use in dogs weighing less than 5 kg.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
See also section "Special precautions for use".

## 3.4 Special warnings

In order to develop an effective worm control programme local epidemiological information and the living conditions of the dog should be taken into account and therefore it is recommended to seek professional advice.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

It is recommended to treat all the animals in the same household concomitantly.

When *Dipylidium caninum* infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection

## 3.5 Special precautions for use

Special precautions for safe use in the target species:

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.
The tolerance of the veterinary medicinal product in young puppies from these breeds has not been investigated.
Clinical signs in Collies are similar to those seen in the general dog population when overdosed (see also section 3.10).

To ensure a correct dosage, body weight should be determined as accurately as possible.

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the veterinary medicinal product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using the veterinary medicinal product, a veterinary consultation is advised to exclude the presence of any concurrent infestation of *Dirofilaria immitis*. In the case of a positive diagnosis, adulticidal therapy is indicated before administering the veterinary medicinal product.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The veterinary medicinal product is not recommended for such animals or only according to the benefit-risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after use.

In case of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.
Do not handle this veterinary medicinal product in case of known hypersensitivity to the active substances or to any of the excipients.

Special precautions for the protection of the environment:

Not applicable.

Other precautions:

Echinococcosis represents a hazard for humans. As echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

### 3.6 Adverse events

Dogs

| | |
|---|---|
| Very rare<br>(<1 animal / 10,000 animals treated, including isolated reports): | Hypersensitivity reaction<br>Systemic disorder (e.g. Lethargy and Anorexia)<br>Neurological disorder (e.g. Muscle tremors, Ataxia and Convulsions)<br>Digestive tract disorder (e.g. Emesis, Diarrhoea, and Drooling) |

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
In a study, this combination of active substances was demonstrated to be well tolerated in breeding bitches, including during pregnancy and lactation.

As a specific study with this veterinary medicinal product has not been performed, use during pregnancy and lactation only according to the benefit-risk assessment by the responsible veterinarian.

### 3.8 Interaction with other medicinal products and other forms of interaction

The concurrent use of the combination praziquantel/milbemycin oxime with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the combination at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the veterinary medicinal product and other macrocyclic lactones. Also no such studies have been performed with reproducing animals.

### 3.9 Administration routes and dosage

Oral use.

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

The veterinary medicinal product should be administered with or after some food.
The tablets are meat flavoured and easy to administer (usually dogs and puppies will accept them voluntarily even without any food).

Depending on the bodyweight of the dog, the practical dosing is as follows:

| Weight | Tablets |
|---|---|
| 5 – 25 kg | 1 tablet |
| >25 – 50 kg | 2 tablets |
| >50 – 75 kg | 3 tablets |

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the veterinary medicinal product can replace the monovalent product for the prevention of heartworm disease.

For treatment of *Angiostrongylus vasorum* infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the veterinary medicinal product and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.
In endemic areas administration of the veterinary medicinal product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of *Thelazia callipaeda*, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, the veterinary medicinal product can replace the monovalent product containing milbemycin oxime alone.

### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No other signs than those observed at the recommended dose have been observed (see section 3.6 “Adverse events”).

### 3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

### 3.12 Withdrawal periods

Not applicable.

## 4. PHARMACOLOGICAL INFORMATION

### 4.1 ATCvet code: QP54AB51

### 4.2 Pharmacodynamics

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of *Streptomyces hygroscopicus* var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of *Dirofilaria immitis*. The activity of milbemycin is related to its action on invertebrate neurotransmission: milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate $GABA_A$ and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.

Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of $Ca^{2+}$) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite.

### 4.3 Pharmacokinetics

After oral administration of praziquantel in the dog, peak serum levels of parent are rapidly attained ($T_{max}$ approximately 0.5-4 hours) and decline quickly ($t_{1/2}$ approximately 1.5 hours); there is a substantial hepatic first-pass effect, with very rapid and almost complete hepatic biotransformation, principally to monohydroxylated (also some di- and tri-hydroxylated) derivatives, which are mostly glucuronide and/or sulfate conjugated before excretion. Plasma binding is about 80%. Excretion is fast and complete (about 90% in 2 days); the principal route of elimination is renal.

After oral administration of milbemycin oxime in dogs, peak plasma levels occur at about 2-4 hours, and decline with a half-life of the unmetabolised milbemycin oxime of 1-4 days. Bioavailability is about 80%.
In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity.

## 5. PHARMACEUTICAL PARTICULARS

### 5.1 Major incompatibilities

Not applicable.

### 5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

### 5.3 Special precautions for storage

Keep the blister in the outer carton.
This veterinary medicinal product does not require any special temperature storage conditions.

### 5.4 Nature and composition of immediate packaging

Aluminium/ Aluminium blister pack (Oriented polyamide/Aluminium/Polyvinyl chloride sealed to Aluminium film).

Pack sizes:
Cardboard box of 2 tablets containing 1 blister of 2 tablets
Cardboard box of 4 tablets containing 2 blisters of 2 tablets
Cardboard box of 24 tablets containing 12 blisters of 2 tablets
Cardboard box of 48 tablets containing 24 blisters of 2 tablets

Not all pack sizes may be marketed.

### 5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

This veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## 6. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

## 7. MARKETING AUTHORISATION NUMBER

Vm 05653/3035

## 8. DATE OF FIRST AUTHORISATION

15 July 2014

## 9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

February 2025

## 10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (*https://medicines.health.europa.eu/veterinary*).

*Gavin Hall*
Approved: 29 May 2025